Clinical Trial Update: SAFety and Efficacy of Human Anti-thymocyte ImmunoGlobUlin SAB-142 ARresting Progression of Type 1 Diabetes [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating the safety and efficacy of SAB-142, a human anti-thymocyte globulin, to arrest progression of Type 1 diabetes mellitus, is c…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 1 Diabetes Mellitus

Drugs mentioned

• SAB-142

Snippet

Sponsor: SAb Biotherapeutics, Inc. | Conditions: Type 1 Diabetes | Phase 2 | Status: RECRUITING